In conclusion, our study reveals a mechanism by which breast tumor evades the CD8+ T cell immune response and provides the rationale for potential therapy by targeting PGRN in combination with immune checkpoint inhibitors for breast cancer patients. Here, CD8A is linked to breast carcinoma.